These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37756226)

  • 1. Improved Detection of Fibrotic Nonalcoholic Fatty Liver Disease in Community-Based Referrals.
    Piao C; Arteaga EJ; Chen S; Guo A; Macdonald ST; Sarkar S
    Metab Syndr Relat Disord; 2023 Nov; 21(9):475-478. PubMed ID: 37756226
    [No Abstract]   [Full Text] [Related]  

  • 2. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gaps in Confirmatory Fibrosis Risk Assessment in Primary Care Patients with Nonalcoholic Fatty Liver Disease.
    Moore JA; Wheless WH; Zhang J; Marsden J; Mauldin PD; Moran WP; Schreiner AD
    Dig Dis Sci; 2023 Jul; 68(7):2946-2953. PubMed ID: 37193930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limitations of Noninvasive Tests-Based Population-Level Risk Stratification Strategy for Nonalcoholic Fatty Liver Disease.
    Behari J; Bradley A; Townsend K; Becich MJ; Cappella N; Chuang CH; Fernandez SA; Ford DE; Kirchner HL; Morgan R; Paranjape A; Silverstein JC; Williams DA; Donahoo WT; Asrani SK; Ntanios F; Ateya M; Hegeman-Dingle R; McLeod E; McTigue K
    Dig Dis Sci; 2024 Feb; 69(2):370-383. PubMed ID: 38060170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.
    Shaheen AA; Riazi K; Medellin A; Bhayana D; Kaplan GG; Jiang J; Park R; Schaufert W; Burak KW; Sargious M; Swain MG
    CMAJ Open; 2020; 8(2):E370-E376. PubMed ID: 32414883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
    Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
    World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of the enhanced liver fibrosis and FIB-4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease.
    Younossi ZM; Stepanova M; Felix S; Jeffers T; Younossi E; Goodman Z; Racila A; Lam BP; Henry L
    Aliment Pharmacol Ther; 2023 Jun; 57(12):1417-1422. PubMed ID: 36967586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced liver fibrosis and the metabolic syndrome in a primary care setting.
    Schreiner AD; Zhang J; Durkalski-Mauldin V; Livingston S; Marsden J; Bian J; Mauldin PD; Moran WP; Rockey DC
    Diabetes Metab Res Rev; 2021 Nov; 37(8):e3452. PubMed ID: 33759300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic performance of non-invasive liver fibrosis risk scores in biopsy-proven non-alcoholic fatty liver disease patients in India.
    Prasad M; Gupta S; Kashyap N; Kapil U
    Indian J Gastroenterol; 2023 Apr; 42(2):192-198. PubMed ID: 37191918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.
    Qadri S; Ahlholm N; Lønsmann I; Pellegrini P; Poikola A; Luukkonen PK; Porthan K; Juuti A; Sammalkorpi H; Penttilä AK; D'Ambrosio R; Soardo G; Leeming DJ; Karsdal M; Arola J; Kechagias S; Pelusi S; Ekstedt M; Valenti L; Hagström H; Yki-Järvinen H
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e2008-e2020. PubMed ID: 34971370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
    Kjaergaard M; Lindvig KP; Thorhauge KH; Andersen P; Hansen JK; Kastrup N; Jensen JM; Hansen CD; Johansen S; Israelsen M; Torp N; Trelle MB; Shan S; Detlefsen S; Antonsen S; Andersen JE; Graupera I; Ginés P; Thiele M; Krag A
    J Hepatol; 2023 Aug; 79(2):277-286. PubMed ID: 37088311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
    Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
    J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting.
    Vieira Barbosa J; Lai M
    Hepatol Commun; 2021 Feb; 5(2):158-167. PubMed ID: 33553966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrosis Risk in Nonalcoholic Fatty Liver Disease Is Related to Chronic Kidney Disease in Older Type 2 Diabetes Patients.
    Sun Y; Hong L; Huang Z; Wang L; Xiong Y; Zong S; Zhang R; Liu J; Zang S
    J Clin Endocrinol Metab; 2022 Aug; 107(9):e3661-e3669. PubMed ID: 35766414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation.
    Dunn W; Song X; Koestler D; Grdinovac K; Al-Hihi E; Chen J; Taylor R; Wilson J; Weinman SA
    J Gastroenterol Hepatol; 2022 Sep; 37(9):1815-1821. PubMed ID: 35613944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients.
    Kobayashi N; Kumada T; Toyoda H; Tada T; Ito T; Kage M; Okanoue T; Kudo M
    Dig Dis; 2017; 35(6):521-530. PubMed ID: 29040984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatokine-based identification of fibrotic NASH and improved risk stratification in a multicentre cohort of NAFLD patients.
    Franck M; John K; Al Aoua S; Rau M; Geier A; Schattenberg JM; Wedemeyer H; Schulze-Osthoff K; Bantel H
    Liver Int; 2023 Dec; 43(12):2668-2679. PubMed ID: 37534777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
    Bril F; McPhaul MJ; Caulfield MP; Clark VC; Soldevilla-Pico C; Firpi-Morell RJ; Lai J; Shiffman D; Rowland CM; Cusi K
    Diabetes Care; 2020 Feb; 43(2):290-297. PubMed ID: 31604692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD.
    Pennisi G; Enea M; Pandolfo A; Celsa C; Antonucci M; Ciccioli C; Infantino G; La Mantia C; Parisi S; Tulone A; Di Marco V; Craxì A; Cammà C; Petta S
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1293-1302.e5. PubMed ID: 35842119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.